CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals
CURE Pharmaceutical recently announced it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents an initial step toward a potential acquisition of the company and the exclusive rights to Coeptis’ approved drug Consensi, the first fixed-dose combination drug for the treatment of comorbid osteoarthritis and hypertension.
“The planned acquisition has the potential to accelerate our 505(b)(2) drug pipeline and expedite our growth with a planned 2020 launch of Consensi,” said Rob Davidson, CEO of CURE Pharmaceutical. “Consensi’s potential to reduce pill burden for patients fits our core mission to improve drug delivery and medication adherence.”
CURE and Coeptis entered into a non-binding term sheet in furtherance of an acquisition for which the final terms and valuation are to be determined.
Additional information concerning this acquisition can be found in the Company’s Form 8-K filed with the Securities and Exchange Commission on November 14, 2019.
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery systems (CUREform™), including CUREfilm® one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with wellness brands, dietary supplement, biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced. For more information, visit www.curepharma.com.
Coeptis Pharmaceuticals, Inc. is a privately held biopharmaceutical company engaged in the acquisition, development and commercialization of innovative products that utilizes the 505(b)(2) pathways. Coeptis licensed FDA-approved Consensi (a combination of amlodipine and celecoxib), which is indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Of the 30 million adults in the US diagnosed with osteoarthritis, 40% also suffer from hypertension. It is in the process of launching Consensi® in the US through a distribution partner with an established sales network to thousands of pharmacies nationwide. Headquartered near Pittsburgh, PA, Coeptis has put together seasoned pharmaceutical executives with demonstrated successes growing revenues and shareholder value and has a robust pipeline of 505(b)(2) products at various stages of development. For more information, visit www.coeptispharma.com.
Total Page Views: 1659
